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                            SUMMARY AND PURPOSES 
Circulating levels of microRNA (miRs) are emergent promising biomarkers 
for cardiovascular disease. Altered expression of miRs has been related to 
heart failure (HF) and cardiac remodeling. To identify the potential source for 
miRs released into the circulation, we measured the concentration gradients 
across the coronary circulation to assess their usefulness to diagnose HF of 
different etiologies. Circulating miRs were measured by TaqMan polymerase 
chain reaction in EDTA-plasma simultaneously obtained from the aorta (Ao) 
and the coronary venous sinus (CVS) in patients with non-ischemic HF (NICM-
HF, n=23), or ischemic HF (ICM-HF, n=23), as well as from control subjects with 
no HF (n=11). We found differential modulation of circulating levels of the 
miRs 423, 34a, 21-3p and 126 across the etiology HF groups. Interestingly, we 
found a positive transcoronary gradient for the miR-423 (p<0.001) and the 
miR-34a (p<0.001), only in the ICM-HF group. On the contrary, a positive 
transcoronary gradient was found for the miR-21-3p (p<0.001) only in the 
NICM-HF group. Finally, despite the dramatic downregulation observed for the 
miR-126 in HF patients (p<0.001) compared to controls, no significant 
variations were observed in its transcoronary gradient. 
The present  findings suggest that circulating levels of miRs are 
differentially expressed in patients with HF of different etiologies. The 
presence of a transcoronary concentration gradient suggests a selective 
release of miR by the failing heart into the coronary circulation. The presence 
of etiology-specific transcoronary concentration gradient in HF patients might 
provide important information to better understand their role in HF, and 
suggests they could be useful biomarkers to distinguish HF of different 
etiologies.   
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1.INTRODUCTION 
The prevalence of Heart Failure (HF) has esponentially increased over the 
last decades and it has been estimated that it will further grow, reaching up to 
10% of the general population in 2030 (1). HF is associated with high mortality 
rates, up to 50% at 5 years and over 70% at 10 years from its first diagnosis (2). 
For this reason, several biomarkers have been developed over the last 
decades, in an attempt to warrant a timely diagnosis and guide the optimal 
clinical management. However, even currently established biomarkers present 
some limitations (3). In particular, they do not allow an etiology-based 
diagnosis. 
Micro RNAs (miRs) are short, non-coding RNAs that modulate gene 
expression at a post-transcriptional level, through sequence specific binding of 
target messenger-RNAs. They are deeply involved in development of the 
cardiovascular system and in the pathophysiology of cardiovascular diseases 
(4-6). Moreover, they can be detected in the circulating blood (7). Since 
circulating miRs are seemingly quite stable, they may be exploited as blood-
borne biomarkers (8). In fact, several studies reported an association between 
circulating levels of specific miRs and cardiovascular diseases, including acute 
myocardial infarction (9-11), myocarditis (12), tako-tsubo (13), acute and 
chronic heart failure (14), stable coronary artery disease (15), in-stent 
restenosis (5,16-17) type 2 diabetes (18), or in association to different levels of 
platelet activity (19-20). 
Importantly, since specific miRs are differentially expressed in different 
cell types, circulating levels of specific miRs might reflect different biological 
alterations, which could provide useful hints to the underlying 
aetiopathogenesis (21). 
5 
 
In this context, we evaluated the transcoronary expression gradients of 
selected circulating microRNAs in heart failure patients, to investigate whether 
a specific release from the heart could be found for different aetiologies 
underlying heart failure. 
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2. METHODS 
2.1 Study sample 
A total of 75 subjects undergoing coronary angiography in the 
catheterization laboratories of the Federico II University of Naples and the 
Magna Graecia University of Catanzaro were enrolled. Patients were classified 
into groups according to their clinical status as follows:  
1) patients with no evidence of cardiovascular disease undergoing 
percutaneous closure of a patent foramen ovale (control group);  
2) patients with HF with an underlying ischemic cardiomyopathy (ICM), 
undergoing cardiac catheterization for implantation of an implantable 
cardioverter defibrillator (ICD);  
3) patients with HF but no underlying ischemic cardiomyopathy (NICM) 
undergoing cardiac catheterization for ICD implantation. 
Exclusion criteria were a known history of leukopenia, thrombocytopenia, 
or severe hepatic or renal dysfunction, as well as ongoing inflammatory or 
malignant disease. In addition, diagnosis of myocarditis or the presence of 
cardiogenic shock were also exclusion criteria. 
On the basis of the expected expression values of miR-423 and its 
standard deviation we calculated that 60 patients would have been required to 
have an 80% chance of detecting a 2-fold increase in miR expression levels 
between  the ICM-HF and the NICM-HF groups (primary study outcome), at a 
significance level of 0.05. However, the total number of HF patients included 
was raised to 64 to account for asymmetrical distribution (consecutive 
inclusion independently of the etiological group) and eventual technical issues 
with detection of miRs in some samples. Patients undergoing cardiac 
7 
 
catheterization for percutaneous occlusion of a PFO with no evidence of 
cardiac impairment during the enrollment period were also included to serve 
as a control group. 
The ethics review board of the Magna Graecia University of Catanzaro, 
Italy, approved the protocols, and the study was conducted in accordance with 
the Declaration of Helsinki. Written informed consent was obtained from each 
individual. 
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2.2 Blood collection and storage 
Blood samples were simultaneously obtained from the coronary venous 
sinus and the aortic bulb during the cardiac catheterization procedure, before 
administration of heparin or any contrast agent and before starting any 
interventional procedure. After centrifugation, samples were transferred to 
RNase/DNase-free tubes and stored at −80°C. 
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2.3 RNA preparation  
Total RNA in plasma was isolated by using TRI Reagent BD following the 
instructions from the manufacturer with modifications. To date, no 
housekeeping miRNA has been established and validated to normalize for the 
miRNA content. Therefore, we supplemented the samples (after addition of 
TRIzol LS) with 5 nmol/L Caenorhabditis elegans miR-39 (cel-miR-39), as 
described previously (8). 
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2.4 Quantitative reverse transcriptase-polymerase chain 
reaction (real time - PCR) analysis 
RNA was obtained as outlined above and diluted 1:10. Diluted RNA 
(5 µL) was reverse transcribed using the TaqMan microRNA Reverse 
Transcription kit (ABI) according to the instructions of the manufacturer. 
Subsequently, 3 µL of the product was used for detecting miRNA 
expression by quantitative (q)PCR using TaqMan microRNA Assay kits 
(ABI) for the corresponding microRNA. cel-miR-39 was used for 
normalizing the data. MicroRNA levels are expressed as 2-
ΔCT[microRNA - cel miR-39]. 
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2.5 Statistical analysis 
The quantitative data were analyzed by means of the Kruskal Wallis, the 
Mann-Whitney U test or the Wilcoxon test (paired sample), as specified in the 
figure legends. For categorical variables, Fischer’s exact test or the χ2 test were 
used. Pearson correlation was used to compare levels of microRNAs with other 
factors. All p-values are two-sided and less than 0.05 was considered a 
statistically significant difference. All statistical calculations were performed 
using IBM SPSS Statistics 23.0 for Windows. 
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3. RESULTS 
3.1 Study sample 
A total of 75 subjects were included. Eleven control subjects undergoing 
percutaneous closure of patent foramen ovale with no further structural heart 
anomalies and normal cardiac function, 41 patients with HF and ICM and 23 
patients with HF and NICM undergoing consecutively cardiac catheterization 
were enrolled. The clinical characteristics of the study groups are summarized 
in table 1. Overall, HF patients presented a marked reduction of left ventricular 
function (left ventricular ejection fraction = 29.7% ± 6.8%) and substantially 
increased plasma NT-ptoBNP levels (2944 ± 5671). Accordingly, 32% of these 
patients were in NYHA class III or IV. As reported in table I, HF patients were on 
optimal medical treatment, with 68% of them on betablockers, 45% on ACE 
inhibitors/ARBs and 45% on potassium sparing diuretics. 
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3.2 MiR selection process 
Specific miRs to be measured in the present study were selected among 
those already known to be associated with heart failure. Briefly, PubMed and 
the Cochrane Library electronic databases were searched for using the 
following keywords: “circulating microRNAs” and “heart failure”. After removal 
of duplicates, a total of 101 articles were available. Full texts of these articles 
were evaluated by two operators (JS and SDR), in order to select the most 
promising circulating miRs to be evaluated in association to Heart Failure. 
Among the most represented, the miR-423 was first selected since several 
reports had described its potential usefulness as a circulating biomarkers in HF, 
despite conflicting results (14,22-24). We also found several reports of 
association between the miR-34a, heart failure and alterations in left 
ventricular function in response to different risk factors and in various LV 
damage models, such as post-ischemic HF (25-26), LV hypertrophy (27), 
hyperglycemic damage (28), or doxorubicin-induced cardiac toxicity (29-30). In 
more recent times, several reports have demonstrated a deep involvement of 
the passenger strand of miR-21, the so called miR-21* (miR-21-3p) in the 
pathophysiology of cardiac hypertrophy and heart failure (31-34). Most 
interestingly, it was found that intercellular transfer of miR-21-3p through 
exosomes plays a key role in these processes (35-36). Not surprisingly, a 
modulation of circulating levels of miR-21-3p were reported in LV dysfunction 
due to LV overload (37). 
In addition, the miR-126 was selected because of multiple original reports 
demonstrating its association with HF. In fact, it is involved in various 
molecular mechanisms underlying HF (38-40). Moreover, several reports 
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described an association between circulating levels of miR-126 and the clinical 
prognosis of HF patients (41-43). 
On the other hand, some miRs were not selected, despite several reports 
were available on their association, due to case-specific reasons. For example, 
although an association of the miR-208 was reported with cardiac damage, 
remodelling, left ventricular function and survival in HF patients (12, 26, 44) it 
was excluded from our analyses for the technical difficulty in measuring the 
extremely low expression levels of this specific miR and the high degree of 
variability observed in our population (data not shown). 
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3.3 MiRs levels in aortic and coronary sinus blood 
As illustrated in figure 1A, circulating plasma levels of the miR-423 were 
significantly elevated in both the aorta (10-fold, p=0.043) as well as the 
coronary sinus (15-fold, p<0.001) only in HF patients with ischemic aetiology 
whereas no substantial differences were observed in the NICM HF group 
(figure 1A). 
Similarly, concentrations of the miR-34a presented a similar, increase in 
both the aorta (6.6-fold, p=0.011) and the CVS (16.5-fold, p<0.001) of ICM HF 
patients (figure 1A).  
On the other hand, levels of the miR-21-3p were significantly increased in 
both the aorta (4.5-fold, p=0.003) and the coronary sinus (11.9-fold, p<0.001) 
of HF patients with non-ischemic aetiology (NICM), as compared to the control 
group. Vice-versa, no significant increase was observed in the group of patients 
with HF of ischemic aetiology (ICM) (figure 1B).  
On the contrary, plasma levels of the miR-126 were substantially reduced 
both in aorta (23.3-fold, p<0.001) and in the CVS (7.8-fold, p<0.001) of patients 
with HF of ischemic origin. A similar modulation was observed in the aorta 
(31.2-fold, p<0.001) and in the CVS (29.3-fold, p<0.001) of patients from the 
NICM HF group (figure 1B).  
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3.4 Transcoronary concentration gradients 
In order to test whether the modulation in the levels of circulating miRs 
observed in HF patients were heart-specific, miR levels were measured in 
blood samples obtained from the aorta and CVS (45). Transcoronary 
concentration gradients were calculated as the ratio between miRs levels 
measured in the coronary venous sinus and those measured in the aorta 
(Figure 2). 
As shown in figure 3A, there was a positive transcoronary concentration 
gradient for the miR-423 only in the group of patients with HF of ischemic 
aetiology (p=0.006), but not in HF patients with NICM (p=0.951), suggesting its 
selective release into the coronary circulation in this etiological subgroup of HF 
(figure 3A). Accordingly, a significant transcoronary gradient was confirmed at 
the Wilcoxon rank test in the ICM HF group (p<0.001), but not in controls 
(p=0.155) or NICM HF patients (p=0.296). 
Similarly, we found a more modest, although significant, positive 
transcoronary concentration gradient for the circulating levels of the miR-34a 
(figure 3B) in the ICM HF group (p<0.001). Accordingly, a significant 
transcoronary gradient was confirmed at the Wilcoxon rank test in the ICM HF 
group (p<0.001), but not in controls (p=0.646) or NICM HF patients (p=0.177). 
In contrast, a positive transcoronary concentration gradient for the miR-
21-3p was found only in the group of patients with HF of non-ischemic 
aetiology (NICM) (p=0.036), suggesting its selective release into the coronary 
circulation in this etiological subgroup of HF (figure 3C). In fact, no gradient 
was documented in the ICM HF group (p=0.798). Accordingly, a significant 
transcoronary gradient was confirmed at the Wilcoxon rank test in NICM HF 
group (p<0.001), but not in controls (p=0.600) or ICM HF patients (p=0.198). 
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Finally, the transcoronary concentration gradient of the circulating miR-
126 presented no significant variation in the group of patients with HF of 
ischemic aetiology (p=0.611) or non-ischemic aetiology (p=0.749), compared to 
the control (figure 3D). 
Importantly, treatment with calcium channel blockers had a significant 
impact on the transcoronary concentration gradient of the miR-423 (r=0.423; 
p=0.002) and miR-126 (r=0.546; p<0.001), while ongoing treatment with ARBs 
was significantly associated with the aortic concentration of the miR-423 
(r=0.294; p=0.032). 
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3.5 Correlation between circulating MiRs concentrations and 
prognostic parameters 
In order to further document an association between circulating 
concentrations of miRs and clinical parameters known to be associated to long-
term prognosis in heart failure patients, we correlated individual miRs levels 
with known prognostic predictors (46-52) and found that the CVS 
concentration of miR-34a was significantly correlated with hemodynamic 
parameters, such as systolic blood pressure (r=0.289; p=0.025) diastolic blood 
pressure (r=0.258; p=0.047), and heart rate (r=0.349; p=0.006), as well as with 
triglyceridemia (r=0.364; p=0.027). Finally, the transcoronary gradient of miR-
34a was correlated with heart rate (r=0.597; p<0.001) and age (r=0.253; 
p=0.041). 
Moreover, the coronary venous plasma concentration of miR-126 was 
also significantly associated with both the systolic (r=0.462; p<0.001) and the 
diastolic (r=0.462; p=0.035) left ventricular function. Similar correlations were 
found with aortic levels of miR-126 (r=0.417 with LV-EF; p=0.001 and r=0.410 
with E/A; p=0.058). In addition, CVS levels of miR-126 were also correlated to 
patients’ age (r=-0.255; p=0.035) and gender (r=-0.277; p=0.020), as well as 
with HDL cholesterol (r=0.389; p=0.023). Similar correlations were found with 
aortic levels of miR-126: r=0.423 with age (p<0.001); r=0.510 with HDL 
cholesterol (p=0.002). Finally, CVS levels of miR-21-3p were significantly 
correlated with both tele-diastolic diameter (TDD) (r=0.358; p=0.011), tele-
systolic diameter (TSD) (r=0.359; p=0.013), and LV-EF (r=-0.283; p=0.026). 
Similarly, aortic levels of miR-21-3p were significantly correlated with LV-EF 
(r=-0.250; p=0.046). Transcoronary concentration gradients of miR-21-3p were 
19 
 
significantly correlated with TDD (r=0.447; p=0.001) and TSD (r=0.472; 
p<0.001). 
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4. DISCUSSION 
The results of the present study document for the first time aetiology-
specific transcoronary concentration gradients of circulating miRs in HF 
patients. In particular, while circulating levels of miR-423 and miR-34a were 
higher in HF patients, particularly in the ischemic aetiology subgroup, 
compared to the control group, expression levels of miR-21-3p were 
dramatically more elevated in the non-ischemic HF subgroup. On the contrary, 
circulating levels of miR-126 were reduced in both HF subgroups. These results 
suggest that the circulating levels of specific miRs reflect at least in part 
specific pathophysiological processes underlying HF in different aetiological 
subgroups. Moreover, the differential modulation of circulating miRs during 
the transcoronary passage further supports this hypothesis and most probably 
reflects cell type-specific expression levels and release mechanisms associated 
with myocardial remodelling in patients with heart failure. 
Several studies reported the involvement of miRs in various pathogenic 
mechanisms underlying heart failure, such as remodelling, hypertrophy, 
apoptosis, and hypoxia (53-54). Importantly, a dynamic modulation of miRs 
was reported across different disease stages (55), or in association with 
specific aetiologies of HF (56), with obvious implications for their prognostic 
potential. 
Among the most investigated circulating miRs in HF, the miR-423 was first 
proposed as a disease biomarker by Tijsen et al., reporting a promising 
discriminatory ability to identify HF-associated dyspnoea from dyspnoea of 
different origins (14). In line with these results, Goren et al. evaluated the 
expression levels of 186 circulating miRs in blood samples from 30 HF patients 
and reported a 1.5-fold increase of miR-423 levels compared to healthy 
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volunteers (57). In this context, Goldraich et al. (58) reported a modest but 
statistically significant transcoronary concentration gradient of the miR-423 in 
16 patients with HF of different aetiologies, despite no difference was 
observed in the levels of miR-423 in venous, arterial or coronary sinus samples 
between HF patients and the control group. Although these conflicting results 
raised come concern and several debates around this research topic (23,59-
60), they kept the spotlights on miR-423. Among the more recent reports, 
Seronde et al. found that lower levels of the circulating miR-423 are associated 
to a poorer prognosis in patients with acute HF (41), while Kuosmanen et al. 
described differential expression levels of miR-423 in pericardial fluid samples 
obtained from HF patients of different aetiologies, although the differences 
reported were not statistically significant, most probably due to the small 
sample size (61). 
Several reasons were suggested to explain the large discrepancies 
reported about the circulating levels of miR-423 and their clinical significance 
in Heart Failure patients. In fact, most studies were small in sample size, they 
often used heterogeneous diagnostic criteria, and grouped different 
pharmacological treatments across different disease stages (23). Most 
importantly, HF patients were evaluated independently of their etiology 
and/or treatment received before and/or during the study. In fact, around half 
of all HF patients included in the studies by Goren et al. and Tijsen et al had an 
ischemic/atherosclerotic etiology but the limited sample size did not allow to 
check for inter-group differences. Hence, the modulation in the expression 
levels of miR-423 could have been driven by the higher levels to be found in 
the ICM subgroup. On the other hand, no specific etiology subgroups were 
reported in the study by Goren and colleagues. 
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On the contrary, in the present study we looked into different etiology 
subgroups and indeed found that multiple circulating miRs are differently 
regulated between ischemic and non-ischemic HF patients. Our results are in 
line with previous findings by Kousmanen et al., reporting different levels of 
the miR-423 in the pericardial fluid, depending on the specific aetiology 
underlying HF (61). Moreover, our finding of a transcoronary concentration 
gradient of miR-423 in one specific aetiology subgroup further suggests that 
the modulation of its expression levels reflects the pathophysiological 
background of HF. 
In addition, the different regulation of the circulating miRs selected for 
the present analysis across different HF subgroups represents a potential 
added value for their clinical use as biomarkers. In fact, if positive 
transcoronary gradients were found for the miR-423 and the miR-34a in 
ischemic HF, patients with non-ischemic HF presented a positive concentration 
gradient for miR-21-3p. On the other hand, the circulating levels of miR-126 
were decreased in both HF subgroups, compared to the control group. Thus, if 
confirmed in large prospective validation studies, the combined measurement 
of these miRs could be very helpful for the etiological diagnosis of HF. 
The finding of a modulation in the levels of these specific miRs is 
particularly interesting, since they are all involved in the pathophysiology of 
left ventricular dysfunction. In particular, the miR-34a had been previously 
associated to left ventricular remodelling and clinical prognosis (26), and a 
modest increase in its levels was reported in HF patients (43). In line with those 
preliminary observations, we found in the present study that miR-34a levels 
are indeed increased with Heart Failure, with a positive transcoronary 
concentration gradient, particularly in the ICM-HF subgroup, which was 
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significantly correlated with hemodynamic parameters, such as heart rate and 
blood pressure. A modulation in the expression levels of both the miR-21-5p 
and the miR-21-3p had been previously reported. However, the latter was 
more interesting as it is involved in the pathophysiology of heart failure and 
left ventricular hypertrophy, and it mediates cell-to-cell communications 
between fibroblasts and cardiomyocytes (35-36). To this regard, in the present 
study CVS levels of the miR-21-3p were significantly correlated with multiple 
parameters of left ventricular function, such as LV ejection fraction, tele-
diastolic- and tele-systolic-diameters. Also in line with our findings, lower 
circulating levels of miR-126 had been reported in HF patients, where its levels 
were correlated with age, left ventricular function, NT-proBNP levels and left 
atrium volume (62). Interestingly, circulating levels of miR-126 were shown to 
correlate with the cardiac repair potential (43). Similarly, miR-126 levels were 
significantly correlated with age, gender, cholesterol levels and left ventricular 
function. 
Measured concentrations of circulating miRs may be affected by multiple 
parameters, including tissue expression, sample processing and storage, the 
release by specific cells into the circulation and their stability. In addition, the 
binding with plasmatic proteins or complex macromolecular complexes, as well 
as their packaging in microvesicles or circulating exosomes also potentially 
affects measured levels of circulating miRs. All these factors may have 
contributed to the inter-individual variance in the measured miRs levels. 
However, the limited sample volume did not allow to test for those factors in 
the present study. 
In summary, circulating concentrations of selected miRs are significantly 
modified upon passage through the coronary circulation. Most interesting, 
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individual miRs present a specific transcoronary concentration gradient in 
different etiological patients’ subgroups, suggesting their potential utility to 
discriminate between different aetiologies underlying HF. Future studies will 
have to address whether the aetiology-specific transcoronary circulation 
gradient of miRs are reflected in different peripheral blood concentrations to 
verify their actual clinical utility in heart failure.                
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6. FIGURES AND TABLES 
 
 ICM-HF 
(n=41) 
NICM-HF 
(n=23) 
ICM-HF + NICM-HF 
(n=64) 
Age (years) 68.4± 10.5 65.1 ±13.2 67.2 ± 11.5 
Male gender 83% 78% 81% 
Family Historyof CAD 28% 
 % 
35% 30% 
NYHA grade Class III/IV  31% 32% 32% 
 
Diabetes  44% 35% 43% 
 
Hypertension 73% 65% 72% 
Smoking 68% 50% 62% 
Dyslipidemia 71% 50% 66% 
 
AF 8% 
 % 
15% 10% 
BMI (kg/m2) 27.3 ± 6.1 29.3 ± 5.4 
 
28.0 ± 5.9 
Systolic BP (mmHg) 119.8 ± 15.1 121.1 ± 17.3 120.2 ± 15.7 
DiastolicBP (mmHg) 74.0 ± 8.1 73.4 ± 12.1 73.8 ± 9.4 
Heart Rate 72.3 ± 14.0 71.5 ± 9.0 
 
72.0 ± 12.5 
 
HDL Chol(mg/dl) 44.5 ± 12.7 52.1 ± 20.7 46.1 ± 14.6 
LDL Chol(mg/dl) 79.6 ± 34.2 73.3 ± 38.8 78.4 ± 34.6 
Triglycerides (mg/dl) 125.4 ± 49.4 132.0 ±76.4 127.1 ± 56.4 
Creatine (mg/dl) 1.3 ± 0.5 1.4 ± 1.3 1.3 ± 0.8 
NT-proBNP (pg/ml) 2507 ± 3731 3742 ± 8205 2944 ± 5671 
DTD (mm) 61.9 ± 6.1 68.2 ± 10.9 63.8 ± 8.3 
DTS (mm) 47.4 ± 7.5 54.5 ± 13.4 49.5 ± 10.0 
LVEF (%) 31.7 ± 6.7 25.3 ± 4.9 29.7 ± 6.8 
β-Blockers  68% 69% 68% 
ACEI/ARB 50% 31% 45% 
CCB 8% 8% 8% 
K sparingduretics 43% 54% 45% 
ASA 75% 39% 66% 
Clopidogrel 38% 15% 32% 
Ticlopidine 5% 8% 6% 
Anticoagulants 20% 15% 19% 
Statins 80% 31% 68% 
HF, Heart Failure; CAD, coronaryarterydisease, NYHA,New York Heart Association; LVEF, 
leftventricularejectionfraction; AF, atrialfibrillation; BMI, Body Mass Index; HDL, high-
densitylipoprotein; LDL, low-densitylipoprotein; NT-proBNP, N-terminal pro-B-type natriureticpeptide; 
DTD, telediastolicdiameter; DTS, telesystolicdiameter; ACEI, angiotensin-convertingenzymeinhibitor; 
ARB, angiotensinreceptorblockers; CCB, Calcium channelblockers. 
 
 
 
 
 
 
              Table 1: baseline characteristics of heart failure patients.  
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 No HF 
(n=11) 
Age (years) 49.0 ± 10.8 
Male gender 18% 
 %  
Family Historyof CAD 18% 
NYHA grade Class III/IV  none 
Diabetes  none 
Hypertension 27% 
Smoking 46% 
Dyslipidemia 18% 
AF none 
BMI (kg/m2) 27.7 ± 12.2 
Systolic BP (mmHg) 125.0 ± 8.7 
DiastolicBP (mmHg) 77.5 ± 6.3 
Heart Rate 65.0 ± 7.0 
HDL Chol(mg/dl) 142.3 ± 19.2 
LDL Chol(mg/dl) 61.0 ± 23.6 
Triglycerides (mg/dl) 94.8 ± 60.7 
Creatine (mg/dl) 0.9 ± 0.2 
HF, Heart Failure; CAD, coronaryarterydisease, NYHA,New York Heart Association; LVEF, 
leftventricularejectionfraction; AF, atrialfibrillation; BMI, Body Mass Index; HDL, high-
densitylipoprotein; LDL, low-densitylipoprotein; NT-proBNP, N-terminal pro-B-type 
natriureticpeptide; DTD, telediastolicdiameter; DTS, telesystolicdiameter. 
  
 
  
 Supplementary Table 1. Baseline characteristics, control group. 
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Figure 1 A. Circulating miRs levels in coronary sinus and aortic blood 
A, levels of the miR-423 and the miR-34a, measured in coronary sinus (gray, 
left) and aortic blood (black, right), in the 3 different groups of patients.  
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B. 
Coronary venous sinus Aorta
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Figure 1 B. Circulating miRs levels in coronary sinus and aortic blood. 
Levels of the miR-21-3p and the miR-126, measured in coronary sinus (gray, 
left) and aortic blood (black, right), in the 3 different groups of 
patients.Between groups comparisons were performed using the Mann-
Whitney U test. 
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Figure 2. Transcoronary concentration gradients: scheme. 
Experimental scheme: transcoronary concentration gradients of circulating 
microRNA are calculated as the ration between the expression levels detected 
in coronary sinus samples and those detected in aortic samples. 
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Figure 3
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Figure 3. Transcoronary concentration gradient of circulating miRs.  
Transcoronary concentration gradients, expressed as the ratio between their 
expression levels in the coronary venous sinus and the aorta ([coronary venous 
sinus]/[aorta]), for the miR-423 (A), miR-34a (B), miR-21-3p (C) and the miR-
126 (D). Between groups comparisons were performed using the Mann-
Whitney U test. 
 
 
 
 
 
 
 
 
